1. Home
  2. NRIX vs GEL Comparison

NRIX vs GEL Comparison

Compare NRIX & GEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$16.79

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Genesis Energy L.P.

GEL

Genesis Energy L.P.

HOLD

Current Price

$17.06

Market Cap

1.9B

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRIX
GEL
Founded
2009
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil Refining/Marketing
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
NRIX
GEL
Price
$16.79
$17.06
Analyst Decision
Strong Buy
Buy
Analyst Count
13
2
Target Price
$29.46
$19.50
AVG Volume (30 Days)
1.3M
251.1K
Earning Date
01-28-2026
02-12-2026
Dividend Yield
N/A
4.39%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$83,980,000.00
$2,893,959,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$20.16
$19.09
P/E Ratio
N/A
N/A
Revenue Growth
53.95
42.14
52 Week Low
$8.18
$10.29
52 Week High
$22.50
$17.77

Technical Indicators

Market Signals
Indicator
NRIX
GEL
Relative Strength Index (RSI) 41.48 57.22
Support Level $16.15 $16.22
Resistance Level $19.65 $17.60
Average True Range (ATR) 1.11 0.54
MACD -0.31 -0.02
Stochastic Oscillator 17.12 61.64

Price Performance

Historical Comparison
NRIX
GEL

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About GEL Genesis Energy L.P.

Genesis Energy LP is a limited partnership company that focuses on the midstream segment of the crude oil and natural gas industry. It engages in providing services to crude oil and natural gas producers, and industrial and commercial enterprises. The company's reportable segments are offshore pipeline transportation, sodium minerals, and sulfur services, onshore facilities and transportation, and marine transportation. It generates maximum revenue from the offshore pipeline transportation segment which conducts crude oil and natural gas pipeline transportation and handling operations in the Gulf of Mexico through its offshore pipeline transportation segment, which focuses on providing a suite of services to integrated and large independent energy companies.

Share on Social Networks: